Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMOXICILLIN & CLAVULANIC ACID

All products: general benefit

Other products in the same Health Canada class (J01C, J01CR) — coverage varies; not interchangeable

  • Piperacillin + tazobactam (Tazocin): not a benefit
  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit

Clavulin (BID) · DIN 02238830 · 400mg & 57mg/5mL · suspension

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clavulin (BID) · DIN 02238830 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2002-12-17 · brand CLAVULIN 400 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1591 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268 · Verify on the e-Formulary ↗ (DIN 02238830)

Source record
DIN 02238830: Clavulin (BID) Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id GSK Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.3850; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238830 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591 M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: lower respiratory tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (10), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications CLAVULIN (amoxicillin / clavulanate potassium) is indicated for the treatment of the following infections when caused by CLAVULIN-susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. • Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus. • Urinary Tract Infections when caused by β-lactamase producing strains of E. coli. While CLAVULIN is indicated only for the conditions listed above, infections caused by ampicillin (amoxicillin) susceptible organisms are also amenable to CLAVULIN treatment due to its amoxicillin content. Furthermore, mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and β-lactamase producing organisms susceptible to CLAVULIN should not require the addition of another an… https://pdf.hres.ca/dpd_pm/00084428.PDF PM date: 2026-04-24 Source product: CLAVULIN 250 F ORAL SUS; DIN 01916874; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.